Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 4 November 2008, doi:10.1136/bmj.a2397
Cite this as: BMJ 2008;337:a2397
Zosia Kmietowicz
1 London
| The first 150 words of the full text of this article appear below. |
The UK National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of drugs to prevent primary and secondary osteoporotic fractures in postmenopausal women.
The guidance recommends a range of treatments, depending on a womans age, her bone density, and how many indicators of fragile bones or risk factors for fracture she has.
It recommends alendronic acid as the first line treatment for primary prevention in women aged 70 or over who are given a diagnosis of osteoporosis and who have a clinical risk factor for the condition or an indicator of low bone density.
NICE defines a diagnosis as a T score of –2.5 or below on dual energy x ray absorptiometry scanning, although it says that women aged over 75 with two or more risk factors for fracture or low bone density can be assumed without a scan to have osteoporosis.
Risk factors
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses